Bellevue Group’s Immunocore IMCR Stock Holding History

Bellevue Group’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.5M	Sell	2,788,245 -8,558	-0.3%	-$253K	1.86%	18
2026 Q1	$84.3M	Hold	2,796,803	–	–	2.01%	17
2025 Q4	$97.1M	Hold	2,796,803	–	–	1.84%	18
2025 Q3	$102M	Buy	2,796,803 +354,973	+15%	+$12.1M	2.11%	15
2025 Q2	$76.6M	Buy	2,441,830 +1,220,036	+100%	+$37.9M	1.69%	16
2025 Q1	$36.3M	Buy	1,221,794 +16,330	+1%	+$490K	0.81%	29
2024 Q4	$35.6M	Hold	1,205,464	–	–	0.68%	33
2024 Q3	$37.5M	Buy	1,205,464 +50,810	+4%	+$1.85M	0.61%	47
2024 Q2	$39.1M	Buy	1,154,654 +182,400	+19%	+$9.3M	0.64%	48
2024 Q1	$63.2M	Sell	972,254 -3,800	-0.4%	-$261K	0.96%	27
2023 Q4	$66.7M	Buy	976,054 +956,204	+4,817%	+$49.7M	1.02%	29
2023 Q3	$1.03M	Buy	+19,850	New	+$1.17M	0.02%	128

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Bellevue Group's IMCR Position: Q2 2026 in Review

Bellevue Group reduced its Immunocore (IMCR) stake by 0.31% in Q2 2026, selling an estimated $253K and leaving 2,788,245 shares worth $88.5M. The position accounts for 1.86% of the portfolio, ranked #18.

Bellevue Group first reported a position in IMCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $102M in Q3 2025. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

Bellevue Group held 2,788,245 shares of Immunocore worth $88.5M as of Q2 2026.
Bellevue Group sold 8,558 Immunocore shares in Q2 2026, an estimated $253K.
Immunocore made up 1.86% of Bellevue Group's portfolio in Q2 2026, its #18 holding.
Bellevue Group first reported a position in Immunocore in Q3 2023 and has held it in 12 quarters since.
Bellevue Group's Immunocore position peaked at $102M in Q3 2025.
136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.